Get the app
US › Healthcare

Pulmonx Corp (LUNG)

US · Healthcare · Medical Devices

$1.78-3.78%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$22.8M
Revenue YoY
-4.6%
Net profit
$-10.1M
EPS
$-0.24
EPS estimate
$-0.28
Net margin
-44.3%

EPS came in at -0.24 against a street estimate of -0.28 — a beat of 14.3%.

Key statistics

Market cap
$76.4M
Forward P/E
28.3
P/B
2.21
Book value
$0.91
EPS (TTM)
$-1.15
52-week high
$2.89
52-week low
$1.13
50-day MA
$2.08
200-day MA
$1.66
Beta
0.34

Analyst view

Analysts rate Pulmonx Corp a buy (3 buy, 2 hold, 0 sell out of 5) with an average price target of $3.40.

Shareholding

Insiders
4.64%
Institutions
62.81%

Largest institutional holders

FundStake
PRIMECAP Management Company10.74%
Morgan Stanley - Brokerage Accounts6.81%
Soleus Capital Management, L.P.6.49%
Vanguard Capital Management, LLC3.80%
ExodusPoint Capital Management, LP2.85%
Almitas Capital LLC2.48%
BlackRock Inc2.05%
Stonepine Capital Management Llc1.90%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pulmonx Corp — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.